All News

Found 239 articles

• Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

  3/15/2022

  Precision BioSciences, Inc. today announced financial results for the fourth quarter and fiscal year ended December 31, 2021.

• B Cell Maturation Antigen BCMA Targeted Therapy Take Center in Multiple Myeloma

  3/7/2022

  B cell maturation antigen (BCMA) is a member of tumor necrosis factor receptor superfamily which pays critical role in regulating B cell proliferation and survival.

• Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

  3/3/2022

  Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the fourth quarter of 2021, and full year ending December 31, 2021.

• Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2021 Financial Results

  3/1/2022

  Jazz Pharmaceuticals plc announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for 2022.

• SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

  2/24/2022

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported financial results for the fourth quarter and full-year periods ended December 31, 2021 and provided an update on recent company developments.

• Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  2/23/2022

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2021.

• SpringWorks Therapeutics to Present at Upcoming Investor Conferences - Feb 01, 2022

  2/1/2022

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that management will present at the following upcoming investor conferences:

• SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET.

• Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder

  12/30/2021

  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD).

• 

  Clinical Catch-Up: December 6-10

  12/13/2021

  There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.

• Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

  12/13/2021

  Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced positive updated results from the Phase 1 UNIVERSAL study of single dose ALLO-715 in relapsed/refractory (r/r) multiple myeloma.

• Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline

  12/11/2021

  Precision BioSciences, Inc., a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion 1 presented at the 63rd American Society of Hematology Annual Meeting.

• SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

  12/10/2021

  SpringWorks Therapeutics, Inc. today announced that the company has entered into a clinical trial collaboration agreement with AbbVie, Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor.

• 

  Clinical Catch-Up: November 29-December 3

  12/6/2021

  Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.

• SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

  12/6/2021

  SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that the first patient has been dosed in a Phase 1b/2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor (GSI), in combination with elranatamab (PF-06863135) Pfizer’s investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.

• SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

  11/29/2021

  SpringWorks Therapeutics, Inc. today announced that it has achieved full enrollment in its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with NF1-associated plexiform neurofibromas (NF1-PN).

• SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

  11/23/2021

  SpringWorks Therapeutics, Inc. today announced that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET.

• Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Precision BioSciences, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.

• SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

  11/4/2021

  SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported financial results for the third quarter and year-to-date periods ended September 30, 2021 and provided an update on recent company developments.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.